Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.58 USD
-0.08 (-4.82%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.59 +0.01 (0.63%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Lexicon Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 0 | 24 | 322 |
Cost Of Goods | 0 | 0 | 0 | 2 | 3 |
Gross Profit | 1 | 0 | 0 | 22 | 319 |
Selling & Adminstrative & Depr. & Amort Expenses | 173 | 101 | 87 | 70 | 177 |
Income After Depreciation & Amortization | -172 | -101 | -87 | -48 | 141 |
Non-Operating Income | 8 | 2 | 0 | 4 | 3 |
Interest Expense | 13 | 3 | 1 | 15 | 21 |
Pretax Income | -177 | -102 | -88 | -59 | 124 |
Income Taxes | 0 | 0 | 0 | 0 | -6 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -177 | -102 | -88 | -59 | 130 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -177 | -102 | -88 | -59 | 130 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -169 | -100 | -87 | -44 | 175 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 0 | 4 | 34 |
Income After Depreciation & Amortization | -172 | -101 | -87 | -48 | 141 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 221.13 | 165.73 | 145.65 | 110.84 | 116.75 |
Diluted EPS Before Non-Recurring Items | -0.79 | -0.62 | -0.60 | -0.52 | 1.35 |
Diluted Net EPS (GAAP) | -0.80 | -0.62 | -0.60 | -0.53 | 1.16 |
Fiscal Year end for Lexicon Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.65 | 1.13 | 0.70 | 0.16 | 0.32 |
Cost Of Goods | 0.17 | 0.03 | 0.07 | 0.01 | 0.01 |
Gross Profit | 1.48 | 1.10 | 0.63 | 0.16 | 0.31 |
SG&A, R&D, and Dept/Amort Expenses | 56.83 | 46.43 | 47.37 | 49.79 | 44.55 |
Income After SG&A, R&D, and Dept/Amort Expenses | -55.35 | -45.33 | -46.74 | -49.63 | -44.24 |
Non-Operating Income | 4.14 | 1.88 | 2.40 | 3.01 | 1.30 |
Interest Expense | 2.21 | 4.95 | 5.42 | 3.90 | 1.96 |
Pretax Income | -53.43 | -48.40 | -49.76 | -50.53 | -44.90 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -53.43 | -48.40 | -49.76 | -50.53 | -44.90 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -53.43 | -48.40 | -49.76 | -50.53 | -44.90 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 310.84 | 245.39 | 244.93 | 244.93 | 204.78 |
Diluted EPS Before Non-Recurring Items | -0.17 | -0.20 | -0.20 | -0.21 | -0.22 |
Diluted Net EPS (GAAP) | -0.17 | -0.20 | -0.20 | -0.21 | -0.22 |